Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%77 Cash-to-Debt is 0.69 as of Dec. 2025, which is 5% below its 10-year median of 0.73. GuruFocus rates SHTDF with a GF Score™ of 77/100 and a GF Value™ of $2.80 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 120 Medical Distribution companies, Sinopharm Group Co ranks better than 52.5% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sinopharm Group Co's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.69.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Sinopharm Group Cocouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Sinopharm Group Co's Cash-to-Debt or its related term are showing as below:
SHTDF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64 Med: 0.73 Max: 0.87
Current: 0.69
During the past 13 years, Sinopharm Group Co's highest Cash to Debt Ratio was 0.87. The lowest was 0.64. And the median was 0.73.
SHTDF's Cash-to-Debt is ranked better than 52.5% of 120
companies
in the Medical Distribution industry
Industry Median: 0.625
vs SHTDF: 0.69
Sinopharm Group Co (OTCPK:SHTDF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Sinopharm Group Co Cash-to-Debt Related Terms
Sinopharm Group Co Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Distribution subindustry, Sinopharm Group Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Cash-to-Debt vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDF) has a Cash-to-Debt of 0.69 as of Dec. 2025. This is near median its historical median of 0.73. Over the past decade, Sinopharm Group Co's Cash-to-Debt has ranged from 0.64 to 0.87. According to the industry distribution chart, Sinopharm Group Co ranks #57 out of 120 companies in the Medical Distribution industry, placing it in the top 47.5%.
Is Sinopharm Group Co's Cash-to-Debt too high?
Sinopharm Group Co's current Cash-to-Debt of 0.69 is near median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 0.87. The Medical Distribution industry median Cash-to-Debt is 0.63. Sinopharm Group Co's value of 0.69 is 10.4% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #57 out of 120 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Cash-to-Debt compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #57 out of 120 companies for Cash-to-Debt. This puts Sinopharm Group Co in the upper half of its industry. The industry median Cash-to-Debt is 0.63. Sinopharm Group Co's value of 0.69 is 10.4% above this benchmark. Historically, Sinopharm Group Co's own Cash-to-Debt has ranged from 0.64 to 0.87 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 0.63, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Distribution company?
The median Cash-to-Debt among Medical Distribution companies is 0.63, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Cash-to-Debt of 0.69 is 10.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Cash-to-Debt is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Cash-to-Debt is 0.69, which is near median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.80, compared to a current price of $2.13 — trading 23.8% below its estimated fair value. The current Cash-to-Debt is 0.69, which is near median its 10-year median of 0.73 and 10.4% above the Medical Distribution industry median of 0.63. Sinopharm Group Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Cash-to-Debt is 0.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 23.8% below its estimated GF Value™ of $2.80.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Cash-to-Debt: 0.69 (near median its 10-year median of 0.73)
GF Value™: $2.80 vs. price of $2.13 (23.8% below fair value)
Industry Position: 10.4% above the Medical Distribution median (#57 of 120)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
77GF Score
Get the complete analysis for SHTDF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
